Dyslipidemia and lower extremity arterial disease.

IF 1.5 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

International Angiology Pub Date : 2024-08-01 Epub Date: 2024-09-20 DOI:10.23736/S0392-9590.24.05266-0

Kosmas I Paraskevas, Pavel Poredos, Agata Stanek, Ales Blinc, Arkadiusz Jawien, Pier Luigi Antignani, Armando Mansilha, Dimitri P Mikhailidis

{"title":"Dyslipidemia and lower extremity arterial disease.","authors":"Kosmas I Paraskevas, Pavel Poredos, Agata Stanek, Ales Blinc, Arkadiusz Jawien, Pier Luigi Antignani, Armando Mansilha, Dimitri P Mikhailidis","doi":"10.23736/S0392-9590.24.05266-0","DOIUrl":null,"url":null,"abstract":"Introduction: Dyslipidemia is an established risk factor for cardiovascular diseases. We aimed to review its role in the pathogenesis of lower extremity arterial disease (LEAD), as well as the effect of lipid-lowering treatment on the progression of LEAD.Evidence acquisition: PubMed/MedLine, EMBASE and Scopus were searched between January 1990 and January 2024 for articles investigating the role of dyslipidemias and hyperlipidemias in the pathogenesis of LEAD. A separate search focused on the effects of lipid-lowering therapy on patients with LEAD.Evidence synthesis: There is evidence that dyslipidemias play a major role in the development of LEAD. All patients with LEAD should receive intensive lipid-lowering therapy for the reduction not only of claudication symptoms and amputation rates, but also of myocardial infarction and cardiovascular event rates.Conclusions: Vascular specialists should keep in mind the pivotal role of dyslipidemia in the pathogenesis and progression of LEAD.","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S0392-9590.24.05266-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Dyslipidemia is an established risk factor for cardiovascular diseases. We aimed to review its role in the pathogenesis of lower extremity arterial disease (LEAD), as well as the effect of lipid-lowering treatment on the progression of LEAD.

Evidence acquisition: PubMed/MedLine, EMBASE and Scopus were searched between January 1990 and January 2024 for articles investigating the role of dyslipidemias and hyperlipidemias in the pathogenesis of LEAD. A separate search focused on the effects of lipid-lowering therapy on patients with LEAD.

Evidence synthesis: There is evidence that dyslipidemias play a major role in the development of LEAD. All patients with LEAD should receive intensive lipid-lowering therapy for the reduction not only of claudication symptoms and amputation rates, but also of myocardial infarction and cardiovascular event rates.

Conclusions: Vascular specialists should keep in mind the pivotal role of dyslipidemia in the pathogenesis and progression of LEAD.

查看原文本刊更多论文

血脂异常与下肢动脉疾病。

导言血脂异常是心血管疾病的既定风险因素。我们旨在回顾血脂异常在下肢动脉疾病（LEAD）发病机制中的作用，以及降脂治疗对下肢动脉疾病进展的影响：在1990年1月至2024年1月期间，在PubMed/MedLine、EMBASE和Scopus上检索了研究血脂异常和高脂血症在LEAD发病机制中作用的文章。另一项检索侧重于降脂治疗对 LEAD 患者的影响：有证据表明，血脂异常在 LEAD 的发病过程中起着重要作用。所有 LEAD 患者都应接受强化降脂治疗，这样不仅能减少跛行症状和截肢率，还能降低心肌梗死和心血管事件的发生率：血管专科医生应牢记血脂异常在 LEAD 发病和进展过程中的关键作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Angiology 医学-外周血管病

CiteScore

2.80

自引率

28.60%

发文量

审稿时长

6-12 weeks

期刊介绍： International Angiology publishes scientific papers on angiology. Manuscripts may be submitted in the form of editorials, original articles, review articles, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work. Duties and responsibilities of all the subjects involved in the editorial process are summarized at Publication ethics. Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (ICMJE).